Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janine Kutzsche

Showing results (11-20 of 49) with videos related to

Pageof 5
Sort By:
Scientific Reports|July 9, 2026
In-depth characterization of the Ca<sub>V</sub>2.2-knockout mouse lineKatharina Wintz, Felix Schumacher, Clemens Pfeiffer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 18, 2017
Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasmaMichelle Hupert, Anne Elfgen, Elena Schartmann, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 9, 2020
Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acidAnne Elfgen, Beatrix Santiago-Schübel, Michelle Hupert, et al.
Molecules (Basel, Switzerland)|April 3, 2021
A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse ModelJulia Post, Vanessa Kogel, Anja Schaffrath, et al.
Molecules (Basel, Switzerland)|October 11, 2017
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's DiseaseJanine Kutzsche, Sarah Schemmert, Markus Tusche, et al.
Nature Communications|May 5, 2025
Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trialJanine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, et al.
Biomedicines|September 28, 2021
Sex-Related Motor Deficits in the Tau-P301L Mouse ModelLuana Cristina Camargo, Dominik Honold, Robert Bauer, et al.
International Journal of Molecular Sciences|July 2, 2021
Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1<sup>G93A</sup> Transgenic MiceJulia Post, Anja Schaffrath, Ian Gering, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 27, 2020
Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I studyJanine Kutzsche, Dagmar Jürgens, Antje Willuweit, et al.
Neurobiology of Disease|November 5, 2018
Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2Sarah Schemmert, Elena Schartmann, Dominik Honold, et al.
Pageof 5

Showing results (11-20 of 49) with videos related to

Sort By:
Pageof 5
Scientific Reports|July 9, 2026
In-depth characterization of the Ca<sub>V</sub>2.2-knockout mouse lineKatharina Wintz, Felix Schumacher, Clemens Pfeiffer, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|December 18, 2017
Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasmaMichelle Hupert, Anne Elfgen, Elena Schartmann, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|October 9, 2020
Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acidAnne Elfgen, Beatrix Santiago-Schübel, Michelle Hupert, et al.
Molecules (Basel, Switzerland)|April 3, 2021
A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse ModelJulia Post, Vanessa Kogel, Anja Schaffrath, et al.
Molecules (Basel, Switzerland)|October 11, 2017
Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's DiseaseJanine Kutzsche, Sarah Schemmert, Markus Tusche, et al.
Nature Communications|May 5, 2025
Oral PRI-002 treatment in patients with MCI or mild AD: a randomized, double-blind phase 1b trialJanine Kutzsche, Nicoleta Carmen Cosma, Gunther Kauselmann, et al.
Biomedicines|September 28, 2021
Sex-Related Motor Deficits in the Tau-P301L Mouse ModelLuana Cristina Camargo, Dominik Honold, Robert Bauer, et al.
International Journal of Molecular Sciences|July 2, 2021
Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1<sup>G93A</sup> Transgenic MiceJulia Post, Anja Schaffrath, Ian Gering, et al.
Alzheimer'S & Dementia (New York, N. Y.)|March 27, 2020
Safety and pharmacokinetics of the orally available antiprionic compound PRI-002: A single and multiple ascending dose phase I studyJanine Kutzsche, Dagmar Jürgens, Antje Willuweit, et al.
Neurobiology of Disease|November 5, 2018
Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2Sarah Schemmert, Elena Schartmann, Dominik Honold, et al.
Pageof 5